Zugocabtagene geleucel

Cell therapy

Also known as CTX112

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Systemic Lupus Erythematosus · Phase 1Diffuse Large B-Cell Lymphoma

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (3)
Follicular Lymphoma
Other / comorbidity
NCT07549698 · CRISPR Therapeutics AG
2026-07-17 – 2033-12 · Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
What this study did
NCT07804004 · CRISPR Therapeutics
2026-11-01 – 2029-12-30 · Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis, Stiff-Person Syndrome
What this study did
Phase 1 (1)
Systemic Lupus Erythematosus

Competitive landscape

This mechanism is crowded: 18 other tracked programmes target it, 7 of them ahead of this one.

This drug's own stage for Diffuse Large B-Cell Lymphoma: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zugocabtagene Geleucel: this drugStage not on recordCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
EpcoritamabApprovedMultispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)
Approved(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
TafasitamabApprovedMonoclonal antibodyCD19Weak signal
NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants
AcalabrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
IbrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
OdronextamabPhase 3Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Purinostat MesylatePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
SHR-A1912Phase 3Antibody–drug conjugateCD79bnot yet gradedNo reviewed efficacy summary in this indication
Zilovertamab VedotinPhase 2/3Antibody–drug conjugateROR1not yet gradedNo reviewed efficacy summary in this indication
Cemacabtagene Ansegedleucel
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Rapcabtagene Autoleucel
Phase 2(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-619
—(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
GLPG5101
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zugocabtagene geleucel to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
December 2029 (1)
Phase 1/2Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease …Not yet recruiting
Est. primary completion 2029-12-30 · NCT07804004 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 1/2Follicular LymphomaRecruiting
Est. primary completion 2030-01 · NCT05643742 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 1Systemic Lupus ErythematosusRecruiting
Est. primary completion 2031-12-31 · NCT06925542 · CT.gov ↗
What to watch
2033 (1)
December 2033 (1)
Phase 1/2Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic PurpuraRecruiting
Est. primary completion 2033-12 · NCT07549698 · CT.gov ↗
What to watch

See the full readout calendar ↗